Hypermarcas registers 39% net profit increase in 2015
Hypermarcas registra um aumento no lucro líquido de 39% em 2015
Intel ID : 234056
| Synopsis |
|
Hypermarcas (BVMF:HYPE3), a distributor of healthcare, beauty, higiene and aesthetics products, registered a 39% increase in its net profit in 2015, compared with the previous year, as reported by the company on 20 February 2016. According to the news, Hypermarcas registered a net profit of BRL 559.9m in 2015, compared with BRL 402.7m in 2014, equivalent to a 39% growth.
(content in portuguese)
A Hypermarcas (BVMF:HYPE3), que se dedica à distribuição de produtos das áreas de saúde, beleza, higiene pessoal e estética, registrou um aumento no lucro líquido de 39% em 2015 em relação à 2014, segundo publicou a própria empresa em 20 de fevereiro de 2016. De acordo com a publicação, a empresa registrou um lucro líquido de BRL 559,9m em 2015 frente aos BRL 402,70m de 2014, o que representa um aumento de 39%. |
Relevant Documents
| Notice / Relevant Fact | 19 Feb 2016 | Hypermarcas_Press_Release_2015.pdf | PT |
|
| Intel ID | 234056 | |
| Value | ND | |
| Native Currency |
Brazilian Real (BRL)
Exchange Rate:  |
|
|
Financial Data - Hypera Pharma
(31 Dec 2024) |
Revenue: - EBITDA: - Net Debt: - |
|
| Date |
 |
|
| Country | |
|
| Region | ||
| Continent | |
|
| Geography | |
|
| Subsector (Old TTR Sectors) |
|
|
| Type |
|
|
| Intel Grade |
|
|
| Source |
|
|
| Tags | |
Target
| Name |
|
||
| Subsector (Old TTR Sectors) |
|
||
| Primary Sector (TTRSC) |
30.01.03 Pharmaceutical R&D, Manufacturing & Distribution 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
||
| Secondary Sectors (TTRSC) |
30.01.01 Biopharmaceuticals 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals 30.01.04 Specialty Pharmaceuticals 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
||
| Country |
|
||
| Website |
|
||
| Description |
|
Legend:
Verified: Confirmed as a party to an active or possible transaction.
Potential: Unconfirmed as a party to an active or possible transaction.
Retained: Confirmed as “Retained” with a general or specific mandate.
Prospect: Advisory “Prospect” in discussions with or pitching services to possible client.
Transactional data is continuously updated by the research team and therefore is subject to change.